IOL Chemicals and Pharmaceuticals share news, announcements and annual reports
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1991 on BSE, Nov 2010 on NSE
Last close ₹180.24up ₹2.59 (1.46%)BSE ₹180.45
Share price at the NSE close on 2 Nov 2026. Previous close ₹177.65.
2 Nov: open ₹179.90, high ₹183.70, low ₹174.72
52-week range of traded prices to 2 Nov 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,291 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.03
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.75
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.55%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 43,11,25121.4% delivered
IOL Chemicals and Pharmaceuticals disputes and clarifications
24 filed, newest first.
May 2026
12 May · Legal
The exchange asked on 11 May 2026
Mar 2026
11 Mar · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act. -2. 2013 or as per Indian Accounting Standard. The response of the Company is awaited.
Sep 2025
8 Sep · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is awaited.
Apr 2023
21 Apr · Legal
The exchange asked on 20 Apr 2023
Dec 2022
22 Dec · Legal
The exchange asked on 21 Dec 2022
Jun 2022
13 Jun · Legal
The exchange asked on 10 Jun 2022
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Mar 2022
10 Mar · Legal
The exchange asked on 9 Mar 2022
Jul 2021
3 Jul · Legal
The exchange asked on 2 Jul 2021
Jun 2021
14 Jun · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to announcement dated 04-Jun-2021, regarding capacity addition. On basis of above the Company is required to clarify following: 1. Existing capacity utilization;2. Period within which the proposed capacity is to be added;3. Investment required;4. Rationale.The response of the Company is awaited.
Aug 2020
3 Aug · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to announcement dated 31-Jul-2020, regarding setting up a new Unit VII for manufacturing of 'Metformin'. On basis of above the Company is required to clarify following: 1. Rationale.The response of the Company is awaited.
Apr 2020
13 Apr · Legal
The exchange asked on 9 Apr 2020
Jan 2020
28 Jan · Legal
The exchange asked on 27 Jan 2020
Nov 2019
15 Nov · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to announcement dated 14-Nov-2019 regarding Board meeting held on November 14, 2019. On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment. The response of the Company is awaited.
Sep 2018
11 Sep · Legal
The exchange asked on 10 Sep 2018
May 2018
18 May · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.
Oct 2017
24 Oct · Legal
The exchange asked on 23 Oct 2017
Nov 2014